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Visceral metastasesAbstract Background: Everolimus (EVE; an inhibitor of mammalian target of rapamycin
positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast
cancer (ABC) who progress on a non-steroidal aromatase inhibitor (NSAI). This is especially
true for patients with visceral disease, which is associated with poor prognosis. The BOLERO-
2 (Breast cancer trial of OraL EveROlimus-2) trial showed that combination treatment with
EVE and exemestane (EXE) versus placebo (PBO) + EXE prolonged progression-free sur-
vival (PFS) by both investigator (7.8 versus 3.2 months, respectively) and independent (11.0
versus 4.1 months, respectively) central assessment in postmenopausal women with HR+,
HER2– ABC recurring/progressing during/after NSAI therapy. The BOLERO-2 trial
included a substantial proportion of patients with visceral metastases (56%).
Methods: Prespeciﬁed exploratory subgroup analysis conducted to evaluate the efﬁcacy and
safety of EVE + EXE versus PBO + EXE in a prospectively deﬁned subgroup of patients with
visceral metastases.
Findings: At a median follow-up of 18 months, EVE + EXE signiﬁcantly prolonged median
PFS compared with PBO + EXE both in patients with visceral metastases (N = 406; 6.8 ver-
sus 2.8 months) and in those without visceral metastases (N = 318; 9.9 versus 4.2 months).
Improvements in PFS with EVE + EXE versus PBO + EXE were also observed in patients
with visceral metastases regardless of Eastern Cooperative Oncology Group performance sta-
tus (ECOG PS). Patients with visceral metastases and ECOG PS 0 had a median PFS of
6.8 months with EVE + EXE versus 2.8 months with PBO + EXE. Among patients with vis-
ceral metastases and ECOG PS P1, EVE + EXE treatment more than tripled median PFS
compared with PBO + EXE (6.8 versus 1.5 months).
Interpretation: Adding EVE to EXE markedly extended PFS by P4 months among patients
with HR+ HER2– ABC regardless of the presence of visceral metastases.
Funding: Novartis.
 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Endocrine therapy (ET) is the cornerstone of systemic
treatment for patients with hormone-receptor-positive
(HR+) advanced breast cancer (ABC). Endocrine treat-
ment with third-generation aromatase inhibitors (letroz-
ole, anastrozole and exemestane) has improved overall
survival (OS) and has become the standard ﬁrst-line
treatment option for postmenopausal women.1,2 Despite
the documented beneﬁts of ET in breast cancer, intrinsic
and acquired resistance remains a common feature that
limits the success of this therapeutic strategy.3 The treat-
ment options for patients with progression on ET oﬀer
limited clinical beneﬁt and poor survival outcomes, lead-
ing to the need for new therapeutic strategies to enhance
the eﬃcacy of ET.4 Recent years have seen major
advances in understanding the mechanisms of resistance
to ET, including up-regulation of the phosphatidylinosi-
tol-3-kinase/Akt/mammalian target of rapamycin
(PI3K/Akt/mTOR) signalling pathway, which is a key
regulator of tumour cell growth, proliferation and
metabolism.5–8 Hyperactivation of this pathway has
been linked to breast cancer pathogenesis, progression
and resistance to endocrine therapy.
Everolimus (EVE; Aﬁnitor, Novartis) is an oral
mTOR inhibitor that acts by binding to mTOR complex
1 and has been approved for treating advanced renal
cell carcinoma, progressive neuroendocrine pancreatictumours and, most recently, ABC progressing after
non-steroidal aromatase inhibitors (NSAIs).9,10 In pre-
clinical studies, use of EVE in combination with ET
resulted in synergistic inhibition of proliferation, induc-
tion of apoptosis and restoration of tumour endocrine
sensitivity.11–13 This concept was recently conﬁrmed in
the randomised, placebo-controlled, phase 3
BOLERO-2 (Breast cancer trial of OraL EveROlimus-
2) study that evaluated the eﬃcacy and safety of the
combination of EVE and exemestane (EXE) in post-
menopausal women with HR+ ABC progressing/recur-
ring after NSAIs.14 Based on investigator assessment,
EVE + EXE improved progression-free survival (PFS)
compared with placebo (PBO)+EXE (median PFS 7.8
versus 3.2 months, respectively).9 These results were
consistent with those based on independent central
assessment (median PFS 11.0 versus 4.1 months for
EVE + EXE and PBO + EXE, respectively).9
The prognosis of patients with HR+ ABC depends on
the pattern and extent of metastatic tumour spread.
Notably, two fundamental patterns of metastatic spread
have been recognised: one with the involvement of soft
tissues and/or bone metastases and one with visceral
organ involvement, including lung, liver, peritoneum or
pleura. Patients with visceralmetastases haveworse prog-
nosis than patients without visceral disease (median sur-
vival 18–24 months versus 40 months in early clinical
trials of ﬁrst-line NSAI therapy).15–17 Unfortunately,
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metastases who have progressed during/afterNSAI treat-
ment. Current treatment guidelines recommend endo-
crine therapy unless the patient has extensive visceral
disease and the need for rapid symptom control; in these
cases chemotherapy is recommended.1,18 However, in
contrast with the current guidelines, most patients with
visceral metastases may be treated with cytotoxic chemo-
therapy regardless of their disease burden, predominantly
because of concerns regarding the longer time needed for
response to ET compared with chemotherapy.19 In fact, a
substantial proportion of patients with visceral disease
who are not in visceral crisis (and therefore not in need
of immediate symptom control) could beneﬁt from con-
tinued ET, thereby delaying the need for chemotherapy
and its associated toxicities. The prespeciﬁed exploratory
subgroup analyses presented here evaluate the eﬃcacy
and safety of EVE + EXE in the prospectively deﬁned
subgroup of patients with visceral metastases in the
BOLERO-2 study.2. Methods
2.1. Trial design
BOLERO-2 is an international, phase 3, multicentre,
randomised, double-blind, placebo-controlled trial
including patients from 189 centres in 24 countries.
The study was designed by the academic investigators
and by representatives of the sponsor, Novartis (Clini-
calTrials.gov identiﬁer NCT00863655).20 Full details
have already been reported.142.2. Patients
Postmenopausal women with HR+, human epider-
mal growth factor receptor-2-negative (HER2–) meta-
static or locally advanced breast cancer not amenable
to curative treatment by surgery or radiotherapy, who
had progressed on prior anastrozole or letrozole (recur-
rence during/within 12 months after adjuvant treatment
or progression during/within 1 month after treatment
for advanced disease), were enrolled in the study.
Patients had baseline Eastern Cooperative Oncology
Group performance status (ECOG PS) 62 with ade-
quate organ and haematologic functions and at least
one measurable lesion or mainly lytic bone lesions in
the absence of measurable disease. Patients who had
received prior ET and a single prior chemotherapy reg-
imen for advanced disease were also eligible. Key exclu-
sion criteria were HER2 overexpression; a history of
brain metastases; prior treatment with EXE or mTOR
inhibitors and bilateral diﬀuse lymphangitic carcinoma-
tosis. Patients with massive lung (>50%) or liver (>1/3)
involvement by sonogram and/or computed tomo-
graphic scan (i.e. disease burden that may constitute avisceral crisis) were initially excluded; however, a proto-
col amendment in February 2010 removed this language
and appreciation of massive visceral involvement in the
lung or liver was left to investigator discretion. Ade-
quate liver function was required for study entry. Enrol-
ment began in June 2009 and continued until January
2011.
The Institutional Review Board at each participating
centre approved the study, and it was conducted in
accordance with Good Clinical Practice principles, the
Declaration of Helsinki, and applicable local regula-
tions. A steering committee supervised the conduct of
the study, and an independent data and safety monitor-
ing committee (IDMC) performed semiannual safety
reviews and reviewed the interim eﬃcacy results. Writ-
ten informed consent was obtained from all patients
before enrolment.2.3. Randomisation and masking
Patients were randomised (at a 2:1 ratio in favour of
EVE + EXE group) to oral EVE (10 mg/day) or match-
ing PBO, both plus EXE (25 mg/day). Randomisation
was stratiﬁed by the presence of visceral metastases
(yes versus no) and documented sensitivity to prior ET
(yes versus no). Visceral metastases included pulmonary,
hepatic, pleural, pleural eﬀusions, peritoneal and ascites
involvement. Any other sites of metastasis (e.g. bone,
lymph nodes, skin) were considered non-visceral.
Patients with visceral metastases irrespective of the pres-
ence of any other metastatic sites (e.g. bone) were cate-
gorised as visceral. All other patients without visceral
metastases were categorised as non-visceral. Endocrine
sensitivity was deﬁned as either objective response or
stable disease lastingP24 weeks after hormonal therapy
for advanced disease or P24 months of adjuvant hor-
monal therapy before disease recurrence.2.4. Treatment
Patients were treated until disease progression, devel-
opment of unacceptable toxicity or withdrawal of con-
sent. Everolimus dose interruptions or reductions were
permitted for the management of adverse events
(AEs). The initial dose reduction allowed in the protocol
was 5 mg daily and a subsequent reduction to 5 mg
every other day.14
Computed tomographic scanning or magnetic reso-
nance imaging of chest, abdomen and pelvis was per-
formed to assess tumours at baseline and every
6 weeks until disease progression. The primary end-
point was PFS, deﬁned as time from randomisation to
ﬁrst documentation of disease progression by the local
investigator according to Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.0, unequivocal
progression of existing bone lesions, appearance of
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points included OS, overall response rate, clinical beneﬁt
rate (CBR), time to deterioration of ECOG PS, safety
and quality of life. Clinical beneﬁt rate was deﬁned as
complete response, partial response or stable disease
for P24 weeks. Adverse events were monitored
throughout the study and graded according to National
Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0.21
2.5. Statistical analysis
The primary eﬃcacy analysis of PFS was assessed
using a log-rank test stratiﬁed according to visceral
metastases and previous hormone sensitivity, and was
estimated between treatment groups using the Kaplan–
Meier method. Hazard ratios and associated 95% conﬁ-
dence intervals (CIs) were assessed by the Cox propor-
tional hazards method as previously described.14 All
analyses were conducted using SAS for Windows, Ver-
sion 9.2 (SAS Institute, Cary, NC).Table 1
Patient demographics and baseline disease characteristics.a
Characteristic Everolimus + exemestane
Visceral (N = 271) Non-visce
Mean age, years (SD) 62.7 (10.3) 62.2 (10.3
P65 years 42% 38%
ECOG PS
0 61% 60%
1 35% 37%
2 2% 1%
Unknown 2% 2%
Time between initial diagnosis and ﬁrst recurrence/metastasis
<3 months 19% 22%
3 to <6 months 2% 1%
P6 months 72% 71%
Unknown 7% 7%
Histology/cytology
Invasive ductal carcinoma 80% 73%
Invasive lobular carcinomas 9% 19%
Other 9% 7%
Not applicable 2% 1%
Number of metastatic sites involved
1 19% 49%
2 33% 27%
3 26% 15%
4 14% 6%
5 6% 2%
>5 2% 1%
Key metastatic sitesb
Lung 43% 12%
Liver 51% 12%
Lung and liver 13% 5%
Bone 71% 83%
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performa
a Percentages are rounded to the nearest whole number.
b 75 patients were mis-stratiﬁed as not having visceral disease at random
and/or liver metastases in the ‘no visceral metastases at baseline’ columns.3. Results
3.1. Patient characteristics and disposition
Between June 2009 and January 2011, 724 women
across 189 centres in 24 countries were randomised to
study treatments (N = 485; EVE + EXE, N = 239;
PBO + EXE). Table 1 shows baseline demographics
and patient characteristics with regard to visceral
involvement. Visceral involvement was reported in 406
patients (56%) and was balanced between treatment
arms. The mean age of patients (62 years) was similar
regardless of visceral involvement. The majority of
patients (>60%) with visceral involvement had ECOG
PS 0 at baseline. The time between initial diagnosis
and ﬁrst recurrence/metastasis was P6 months for the
majority of patients (70%) with or without visceral dis-
ease. The majority of patients had invasive ductal carci-
noma irrespective of visceral involvement. Among
patients with visceral involvement, 84% had two or
more metastatic sites and 50% had three or morePlacebo + exemestane
ral (N = 214) Visceral (N = 135) Non-visceral (N = 104)
) 61.3 (9.9) 61.1 (9.6)
35% 32%
62% 56%
33% 38%
2% 4%
2% 3%
21% 15%
2% 2%
70% 77%
7% 6%
80% 71%
13% 22%
7% 7%
1% 0%
11% 47%
36% 34%
29% 13%
18% 6%
4% 1%
2% 0%
47% 14%
47% 9%
16% 4%
73% 84%
nce status; SD, standard deviation.
isation, which accounts for the small percentages of patients with lung
Fig. 1. Trial proﬁle. Abbreviation: ITT, intent-to-treat population.
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approximately 45% had lung metastases, 50% had liver
metastases and 14% had both lung and liver metastases.
In patients without visceral disease (44% of the overall
population), bone was the most common site of metas-
tases (83%). The distribution of metastatic sites was well
balanced across treatment arms. It is important to note
that 75 patients were mis-stratiﬁed as not having visceral
disease at randomisation; however, a sensitivity analysis
for PFS using the stratiﬁcation factor of visceral metas-
tases based on patient medical records in the clinical
report forms showed similar results as the analysis using
the stratiﬁcation factor based on randomisation (results
not shown) (Fig. 1).
At a median follow-up of 18 months, 91 patients
continued to receive study treatment: 81 (17%) in the
EVE + EXE arm and 10 (4%) in the PBO + EXE arm.
The most common reason for treatment discontinuation
was disease progression (62% EVE + EXE; 89%
PBO + EXE).
3.2. Eﬃcacy
The trial met its primary end-point, PFS, which was
signiﬁcantly improved with EVE + EXE compared with
PBO + EVE overall, and in all subgroups deﬁned bystratiﬁcation factors (i.e. sensitivity to prior hormonal
therapy and the presence of visceral metastasis). Treat-
ment with EVE resulted in signiﬁcant improvement in
PFS irrespective of visceral involvement. Among
patients with visceral metastases, median PFS per local
investigator assessment was 6.8 months in patients trea-
ted with EVE + EXE versus 2.8 months for those trea-
ted with PBO + EXE (hazard ratio 0.47; 95% CI 0.37–
0.60; p < 0.05) (Fig. 2). Results based on central assess-
ment for patients with visceral metastases treated with
EVE + EXE versus PBO + EXE were consistent (8.3
versus 2.9 months; hazard ratio 0.46). Patients who did
not have visceral metastases at baseline had a 5.7-month
extension in median PFS per local investigator assess-
ment with EVE + EXE versus PBO + EXE (9.9 versus
4.2 months; hazard ratio 0.41; 95% CI 0.31–0.55;
p < 0.05) (Fig. 2).
Improvements in PFS with EVE + EXE versus
PBO + EXE were also observed in all patients with vis-
ceral metastases regardless of ECOG PS. Patients who
had visceral involvement at baseline with ECOG PS 0
had a median PFS of 6.8 months with EVE + EXE ver-
sus 2.8 months with PBO + EXE (hazard ratio 0.54,
95% CI 0.4–0.73, p < 0.05) (Table 2). Among patients
with visceral involvement at baseline and ECOG PS
P1, EVE + EXE treatment also improved median
Fig. 2. Kaplan–Meier curve for PFS in patients (A) with and (B) without visceral involvement. Abbreviations: CI, conﬁdence interval; EVE,
everolimus (10 mg/day); EXE, exemestane (25 mg/day); PBO, placebo; PFS, progression free survival.
Table 2
Analysis of PFS by visceral disease and performance status at baseline.
Everolimus + exemestane Placebo + exemestane Hazard ratio
(95% Cl)Pts Events Median PFS
(months)
Pts Events Median PFS
(months)
Patients with visceral disease at
baseline
271 188
(69.4%)
6.83 135 116
(85.9%)
2.76 0.47 (0.37–0.60)
ECOG PS 0 167 114
(68.3%)
6.83 84 70 (83.3%) 2.79 0.54 (0.40–0.73)
ECOG PS P1 100 71 (71.0%) 6.77 48 43 (89.6%) 1.45 0.35 (0.23–0.52)
Abbreviations: CI, conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, progression-free survival; pts,
patients.
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Fig. 3. Kaplan–Meier curve for PFS in patients with bone-only metastases. Abbreviations: CI, conﬁdence interval; EVE, everolimus (10 mg/day);
EXE, exemestane (25 mg/day); PBO, placebo; PFS, progression free survival.
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1.5 months; hazard ratio 0.35; 95% CI 0.23–0.52;
p < 0.05) (Table 2). Improvement in PFS with
EVE + EXE was also observed in patients who had
bone-only lesions at baseline (12.88 versus 5.29 months;
N = 105 for EVE + EXE; N = 46 for PBO + EXE; haz-
ard ratio 0.33; 95% CI 0.21–0.53; p < 0.05) (Fig. 3).
Consistent with the longer PFS seen in EVE + EXE
treated patients; clinical beneﬁt rate (CBR) was also sig-
niﬁcantly higher among patients who received
EVE + EXE irrespective of visceral involvement
(Table 3). Clinical beneﬁt rate was highest among
patients without visceral disease at baseline treated with
EVE + EXE (59.8%; 95% CI 52.9%–66.4% versus
31.7%; 95% CI 22.9%–41.6% for PBO + EXE). Patients
with visceral disease treated with EVE + EXE had a
similar CBR independent of ECOG PS (ECOG PS 0,
43.7%; ECOG PS P1, 44%). An increase in CBR was
also observed among patients with visceral metastases
at baseline and ECOG PSP1 treated with EVE + EXE
(44%) compared with PBO + EXE (8.3%) (Table 3).
Additionally, the time to 5% deterioration in global
health status was consistently longer with EVE + EXE
versus PBO + EXE in patients with (7.82 versus
4.40 months; hazard ratio 0.74; 97.5% CI 0.52–1.05) or
without (8.38 versus 7.03 months; hazard ratio 0.73;
97.5% CI 0.49–1.08) baseline visceral metastases
(Fig. 4).3.3. Safety
Similar to the safety proﬁle observed in the overall
population,14 in this subgroup analysis patients treated
with EVE + EXE had a higher incidence of treatment-
emergent AEs compared with those treated withPBO + EXE. In general, the incidence of AEs among
treatment groups was similar irrespective of the presence
of visceral metastases at baseline, and there was no indi-
cation of increased risk of speciﬁc AEs (e.g. metabolic
abnormalities or elevated levels of liver enzymes) in
patients with visceral metastases (Table 4). The most
common treatment-emergent AEs among patients with
visceral disease at baseline receiving EVE + EXE were
stomatitis, rash, fatigue, decreased appetite and diar-
rhoea. The type and frequency of these AEs are consis-
tent with those observed in the overall study population
receiving EVE + EXE.144. Discussion
The present study is a subgroup analysis from the
BOLERO-2 trial that provides support for the eﬃcacy
and safety of combined treatment with EVE and EXE
to enhance sensitivity to ET in postmenopausal women
with visceral metastases from HR+ ABC and progres-
sion during/after NSAI treatment. The combination of
EVE + EXE prolonged PFS by 4 months in patients
with visceral metastases (6.8 versus 2.8 months). This
PFS improvement was conﬁrmed by independent cen-
tral assessment and is consistent with that observed in
the overall population in the BOLERO-2 trial.22 A supe-
rior CBR (44%) was also observed among these
patients for the combination arm versus the EXE-only
arm irrespective of their ECOG PS. The majority of
patients (69% in the overall population; 84% in patients
with visceral metastases at baseline) in the BOLERO-2
trial had metastases at two or more sites and, although
such patients may receive chemotherapy in clinical
practice, these results show that they can indeed
gain substantial beneﬁt from the combination of
Table 3
Analysis of clinical beneﬁt rate by visceral disease and performance status at baseline.
Everolimus + exemestane Placebo + exemestane
n/N % 95% CI n/N % 95% CI
No visceral disease at baseline 128/214 59.8 (52.9–66.4) 33/104 31.7 (22.9–41.6)
Visceral disease at baseline 121/271 44.6 (38.6–50.8) 30/135 22.2 (15.5–30.2)
ECOG PS 0 73/167 43.7 (36.1–51.6) 23/84 27.4 (18.2–38.2)
ECOG PS P1 44/100 44.0 (34.1–54.3) 4/48 8.3 (2.3–20.0)
Abbreviations: CI, conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group performance status.
Fig. 4. Kaplan–Meier curve for time to 5% deterioration in global health status in patients (A) with and (B) without visceral involvement.
Abbreviations: CI, conﬁdence interval; EVE, everolimus (10 mg/day); EXE, exemestane (25 mg/day); GHS, global health status; PBO, placebo;
TDD, time to deﬁnitive deterioration.
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Table 4
Any-grade adverse eventsa with P20% incidence.b
Adverse event Everolimus + exemestane Placebo + exemestane
Visceral (N = 269) (%) Non-visceral (N = 213) (%) Visceral (N = 135) (%) Non-visceral (N = 103) (%)
Stomatitis 59 59 13 10
Rash 40 39 4 10
Fatigue 40 36 29 25
Decreased appetite 36 24 15 11
Diarrhoea 34 34 16 22
Nausea 33 27 29 28
Weight decreased 30 25 7 8
Cough 27 24 13 11
Dysgeusia 24 19 6 6
Headache 20 25 15 15
Hyperglycaemia 16 12 2 2
AST increased 15 12 5 6
Pneumonitis 14 19 0 0
ALT increased 12 13 4 5
Interstitial lung disease 2 6 0 0
Hyperlipidaemia 1 1 1 0
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Note: Percentages are rounded to the closest whole number.
a Adverse event incidences are reported for the safety population.
b Metabolic abnormalities and pulmonary adverse events are reported even if the incidence was <20% because these are class eﬀects with
mammalian target of rapamycin inhibitors.
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EVE + EXE was maintained in patients who had vis-
ceral disease per stratiﬁcation criteria. Therefore, this
combination oﬀers a viable alternative treatment
approach with less toxicity compared with most cyto-
toxic chemotherapy agents.
Alterations in signalling via the serine threonine kinase
mTOR are common in cancer and, thus, mTOR is being
actively pursued as a therapeutic target. Previous reports
indicate that blocking the PI3K/Akt/mTOR pathway
serves as a novel approach to restore or enhance sensitiv-
ity to ET.23 In the TAMRAD study, EVE added to
tamoxifen delayed time to disease progression (8.6 versus
4.5 months for tamoxifen alone) and improved OS (med-
ian not reached versus 24 months, p = 0.002) in patients
with HR+, HER2–, metastatic breast cancer.24 However,
the patient population was too small to perform subset
analysis on the 53% of patients with visceral disease.24
The results from the current subset analysis therefore
add to the growing evidence supporting the addition of
an mTOR inhibitor to ET as a means to enhance endo-
crine sensitivity in patients with visceral disease. Overall,
this analysis demonstrates that EVE, an mTOR inhibitor,
given at a dose of 10 mg/day in combination with the ste-
roidal AI EXE at 25 mg/day, is a valuable treatment
option for postmenopausal women with visceral metasta-
ses from ABC who have progressed on prior NSAI treat-
ment, have few symptoms and retain a reasonably good
performance status.
Visceral metastases in patients with ABC are associated
with poor prognosis. In routine clinical practice, these
patients are likely to receive chemotherapy, especially after
failure of prior NSAI therapy. Although chemotherapymay be necessary when rapid symptom control is needed
(i.e. patients with highly symptomatic visceral disease
and/or a high disease burden in vital organs), many
patients with visceral metastases have lower disease burden
and may beneﬁt from ET.18,19 By extending the number of
treatment options available in such cases, it may be possi-
ble to postpone cytotoxic chemotherapy and thereby delay
the burden of treatment-related myelosuppression and
other AEs.18 The analyses presented herein add to the
body of evidence supporting delaying chemotherapy for
HR+ disease in the advanced setting.
Although AEs in the present analysis were more fre-
quent with EVE + EXE versus EXE alone, they were
generally manageable and occurred irrespective of vis-
ceral involvement. The AEs observed with EVE in this
study (e.g. stomatitis, rash, fatigue, decreased appetite,
diarrhoea and hyperglycaemia) are consistent with those
observed with EVE monotherapy in other tumour types
(e.g. renal cell carcinoma) and are manageable with
established strategies including dose adjustments.9,25
Furthermore, quality of life as measured by time to
5% deterioration in global health status was maintained
in patients receiving EVE.
A limitation of this study is that patients with exten-
sive visceral disease were initially explicitly excluded.
However, the protocol was amended such that appreci-
ation of massive visceral involvement in the lung or liver
was left to investigator discretion. Although not the
intention of the amendment, some patients with exten-
sive visceral disease may have entered the study.
Although a subset of women with visceral metastases
will continue to require chemotherapy for rapid clini-
cally signiﬁcant symptom control, the combination of
2630 M. Campone et al. / European Journal of Cancer 49 (2013) 2621–2632EVE + EXE oﬀers an important alternative for the large
proportion of patients whose visceral metastases are not
immediately life-threatening. The convenience of this
all-oral combination, together with favourable tolerabil-
ity, adds to the armamentarium against HR+ ABC pro-
gressing after NSAI therapy.
4.1. Panel: research in context
4.1.1. Prespeciﬁed exploratory subgroup analysis
A subgroup analysis of the BOLERO-2 phase 3 study
was conducted to evaluate the eﬃcacy and safety of
EVE + EXE versus PBO + EXE in a prospectively
deﬁned subgroup of patients with visceral metastases. In
BOLERO-2, postmenopausal women with HR+, HER2–
ABC who had recurred or progressed during/after anas-
trozole or letrozole were enrolled in the study. Patients
were randomised (at a 2:1 ratio in favour of EVE + EXE
group) to oral EVE (10 mg/day) or matching PBO, both
plus EXE (25 mg/day). The present analyses were based
on stratiﬁcation by the presence of visceral metastases
(yes versus no) at randomisation. Visceral metastases
included pulmonary, hepatic, pleural, pleural eﬀusions,
peritoneal and ascites involvement. Any other sites of
metastasis (e.g. bone, lymph nodes and skin) were consid-
ered non-visceral. Patients with visceral metastases, irre-
spective of the presence of any other metastatic sites (e.g.
bone), were categorised as visceral. All other patients with-
out visceral metastases were categorised as non-visceral.4.1.2. Interpretation
Adding EVE to EXE markedly extended PFS by
more than 4 months among patients with HR+,
HER2– ABC regardless of the presence of visceral
metastases. Although a subset of women with visceral
metastases will continue to require chemotherapy for
rapid clinically signiﬁcant symptom control, the combi-
nation of EVE + EXE oﬀers an important alternative
for the large proportion of patients whose visceral
metastases are not immediately life-threatening. The
convenience of this all-oral combination, together with
favourable tolerability, adds to the armamentarium
against HR+ ABC progressing after NSAI therapy.Authors’ contributions
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